ImmunityBio Secures $100 Million Financing to Expand Cancer Immunotherapy and Global Growth
Published: 27 Apr 2026
Author: Towards Healthcare
ImmunityBio Strengthens Balance Sheet with $100 Million of Financing Transactions, Including $75 Million of Non-Dilutive Financing to Support Global Expansion and Advancement of Broader Immunotherapy Pipeline.
ImmunityBio, Inc announced it has secured $75 million in non-dilutive financing under its existing Royalty Interest Purchase Agreement (RIPA) with Oberland Capital, increasing the total committed capital under the Agreement to $375 million. This agreement maintains existing terms, with a modest increase in the royalty payback rate while maintaining the royalty cap.
President and CEO of ImmunityBio, Richard Adcock, said this additional non-dilutive financing gives us the capacity to continue scaling our commercial efforts and expanding globally following recent ANKTIVA® approvals, while positioning us to take full advantage of the growth opportunities ahead.
According to Towards Healthcare, the Non-antibody fusion proteins market is projected to experience significant growth, with estimates suggesting the market size will increase from USD 10.89 billion in 2026 to approximately USD 27.19 billion by 2035, representing a compound annual growth rate (CAGR) of 10.7% from 2026 to 2035. Growth is driven by the growing adoption of personalised medicine, which further boosts demand for fusion proteins, as they are used in developing targeted therapies tailored to individual patient needs. Demand for innovative therapies is a significant growth driver.
About ANKTIVA® (nogapendekin alfa inbakicept-pmln)
The cytokine interleukin-15 (IL-15) plays a crucial role in the immune system by affecting the development, maintenance, and function of key immune cells—NK and CD8+ killer T cells that are involved in killing cancer cells.
By activating NK cells, ANKTIVA overcomes the tumor escape phase of clones resistant to T cells and restores memory T cell activity with resultant prolonged duration of complete response. ANKTIVA is a first-in-class IL-15 receptor superagonist IgG1 fusion complex, consisting of an IL-15 mutant (IL-15N72D) fused with an IL-15 receptor alpha, which binds with high affinity to IL-15 receptors on NK, CD4+, and CD8+ T cells.
This fusion complex of ANKTIVA mimics the natural biological properties of the dendritic cell membrane-bound IL-15 receptor alpha, driving the activation and proliferation of NK cells with the generation of memory killer T cells that have retained immune memory against these tumor clones.
About ImmunityBio
The company is based in California, focused on innovating, developing, and commercialising next-generation immunotherapies designed to activate the patient’s immune system and deliver durable protection against cancer and infectious diseases. Our approach harnesses both the adaptive and innate immune systems to restore immune function and generate lasting immunological memory in patients.
The company has collaboration agreements with the National Cancer Institute and Serum Institute of India Private Limited, and holds a license agreement with 3M Innovative Properties Company and Access to Advanced Health Institute.
A recent report by Towards Healthcare highlights that the Non-antibody fusion proteins market is witnessing growth due to the demand for targeted therapies and the need for innovative solutions, whereas the market is characterised by a diverse array of players, from established pharmaceutical giants to emerging biotech firms, all vying for a share of this promising sector.
North America is experiencing significant growth, driven by advancements in protein engineering and the increasing demand for targeted therapies. The market is expected to dominate and grow at a rapid pace, with key players for product innovation and strategic collaboration.
Asia Pacific is driven by increasing healthcare expenditures, a growing biotechnology sector, and a rising prevalence of chronic diseases. The region's market share, government policies, and a large patient pool make it an attractive area for investment and innovation in the fusion protein market.